Jupiter Neurosciences Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company known for developing JOTROL—an enhanced oral resveratrol formulation with antioxidant and anti-inflammatory effects—has introduced Nugevia, a direct-to-consumer longevity product line. The line includes supplements aimed at improving mitochondrial support, mental clarity, and beauty from within, with cognitive health as a central focus. Nugevia MND, a scientifically formulated supplement designed to protect and enhance cognitive function, is expected to account for about 60% of the company's sales by volume.
“Brain health is central to Jupiter’s DNA as a neuroscience company, and consumer awareness in this area is accelerating rapidly,” said a Jupiter Neurosciences spokesperson. “Our Nugevia MND formulation directly builds on our pharmaceutical expertise in neuroinflammation and CNS function, making it the most natural bridge between our clinical work and consumer wellness line. MND reflects the growing demand for cognitive support driven by aging populations and proactive consumers seeking mental clarity, focus and resilience.” The global brain health supplement market is projected to reach about $23 billion by 2030, growing at a CAGR of around 13%.
Jupiter Neurosciences has a deep history in diseases of the brain, thanks to its work developing drugs for central nervous system disorders such as Alzheimer's and Parkinson's. Its supplement business, comprised of Nugevia MND, Nugevia GLO, and Nugevia PWR, builds on its clinical research addressing neuroinflammation, mitochondrial health, and cellular protection.
All Nugevia products are derived from JOTROL, which is designed to deliver therapeutically relevant levels of resveratrol. Jupiter Neurosciences overcame previous bioavailability challenges, achieving about nine times higher absorption and proven CNS penetration. A phase one trial of JOTROL demonstrated blood plasma levels 8-10-fold higher than naïve resveratrol, and the phase two trial focuses on treating Alzheimer’s, Parkinson’s, and other CNS diseases. JOTROL has patents in the U.S., Europe, China, Hong Kong, and Japan, protected through 2036.
What sets Nugevia apart from single-ingredient supplements, according to the company, is its precision-engineered “intelligent stacking” of synergistic compounds designed to enhance cellular resilience, support blood-brain barrier delivery, and promote system-wide optimization. The company also leverages endorsements from brand ambassadors including former tennis great Annika Sörenstam, NBA legend Chris Webber, scientist Charbel Moussa, and biohacker Jean Fallacar, who share how they use Nugevia in their daily lives.
“Jupiter Neurosciences is first and foremost a clinical-stage biotech company that has spent the past decade developing therapies for complex central nervous system disorders. What makes our entry into the supplement space so unique is that we’re coming into it from the clinic, not the other way around,” a company spokesperson said. “It’s a natural evolution of our dual-path strategy: advancing prescription therapies for patients while empowering everyday consumers with credible, evidence-based solutions for healthy aging.”
